Global Antidiabetic Drug Market

Antidiabetic Drug Comprehensive Study by Type (Type II Diabetes), Drug Type (Generic, Branded), Route of Administration (Oral (eg. oral hypoglycemic), Intravenously (eg. insulin and GLP-1 receptor agonists)), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Drug Class (Biguanides (Metformin), Sulfonylureas (Glimepiride), Meglitinides (Repaglinide), Thiazolidinediones (Pioglitazone), Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin), α-Glucosidase inhibitors (Acarbose)) Players and Region - Global Market Outlook to 2026

Antidiabetic Drug Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 7.35%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Antidiabetic Drug Market Scope?
According to the International Diabetes Federation estimates, the prevalence of diabetes is anticipated to escalate from 366 million in 2011 to 552 million by 2030. Statistically, approximately 80% to 90% of the patients diagnosed with diabetes are also treated with obesity. Moreover, Type I and type II diabetes is expected to propel the demand for oral hypoglycemic drugs as it is a proven diabetes controller among patients globally. Further, the rising investments on healthcare facilities have led the pharmaceutical industry to experiment with more pipeline drugs for diabetes which in turn is fostering the global anti diabetes drugs market.

The Antidiabetic Drug market study is being classified by Type (Type II Diabetes) and major geographies with country level break-up. According to AMA, the Global Antidiabetic Drug market is expected to see growth rate of 7.35% and may see market size of USD110896.57 Million by 2026.

Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Antidiabetic Drug market throughout the predicted period.

Sanofi-Aventis (France), Eli Lilly and Company (United States), Oramed Pharmaceuticals (Israel), Takeda Pharmaceuticals Private Limited (Japan), Boehringer Ingelheim (Germany), Novo Nordisk (Denmark), Halozyme Therapeutics (United States), Bristol-Myers Squibb Company (United States), Pfizer Inc. (United States), Tonghua Dongbao Pharmaceutical Co., Ltd. (China), Astellas Pharma Inc.(Japan), Merck and Co.Inc.(United States) and AstraZeneca plc (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Janssen Pharmaceuticals, Inc.(Belgium), Biocon (India) and Wockhardt Limited (India).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Antidiabetic Drug market by Type, Application and Region.

On the basis of geography, the market of Antidiabetic Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

September 2017, Biocon and JDRF, a leading global organization funding Type 1 diabetes (T1D) research and advocacy worldwide, announced a partnership to support a global study with an oral insulin drug candidate, Insulin Tregopil, in people with T1D. and Insulin Tregopil, an oral insulin molecule being developed by Biocon, is one of the advanced programs in the global oral insulin space. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus holding a promise to transform T1D management
January 2019, The Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration announced the benefits of Zynquista (sotagliflozin) outweighed the risks to support approval. Sotagliflozin is an investigational oral dual SGLT1 and SGLT2 inhibitor under regulatory review as an adjunct to insulin for the treatment of adults with type 1 diabetes (T1D).

Influencing Market Trend
  • Introduction of new Product Launch and Commercialization of Products in the Pipeline
  • Rising Demand for Oral Drugs to Reduce Sugar Level among Diabetic Population

Market Drivers
  • Increasing Prevalence of Diabetes Population among Patients
  • Rising Disposable Income and Sedentary Lifestyle of Consumers
  • Increasing Government Support and Awareness Related to Diabetes

Opportunities
  • High Investment in Healthcare Sector by the Government to Improve Medical Infrastructure

Restraints
  • High Cost of Antidiabetic Drugs may hamper the Market Growth

Challenges
  • Stringent Government Regulations and Lack of Awareness about Therapeutic Drug Treatment for Diabetes


Key Target Audience
Anti-Diabetes Drug Manufacturers, Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Traders/Suppliers & Distributors

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Type II Diabetes
By Drug Type
  • Generic
  • Branded

By Route of Administration
  • Oral (eg. oral hypoglycemic)
  • Intravenously (eg. insulin and GLP-1 receptor agonists)

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Drug Class
  • Biguanides (Metformin)
  • Sulfonylureas (Glimepiride)
  • Meglitinides (Repaglinide)
  • Thiazolidinediones (Pioglitazone)
  • Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin)
  • α-Glucosidase inhibitors (Acarbose)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Diabetes Population among Patients
      • 3.2.2. Rising Disposable Income and Sedentary Lifestyle of Consumers
      • 3.2.3. Increasing Government Support and Awareness Related to Diabetes
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulations and Lack of Awareness about Therapeutic Drug Treatment for Diabetes
    • 3.4. Market Trends
      • 3.4.1. Introduction of new Product Launch and Commercialization of Products in the Pipeline
      • 3.4.2. Rising Demand for Oral Drugs to Reduce Sugar Level among Diabetic Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antidiabetic Drug, by Type, Drug Type, Route of Administration, Distribution Channel, Drug Class and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Antidiabetic Drug (Value)
      • 5.2.1. Global Antidiabetic Drug by: Type (Value)
        • 5.2.1.1. Type II Diabetes
      • 5.2.2. Global Antidiabetic Drug by: Drug Type (Value)
        • 5.2.2.1. Generic
        • 5.2.2.2. Branded
      • 5.2.3. Global Antidiabetic Drug by: Route of Administration (Value)
        • 5.2.3.1. Oral (eg. oral hypoglycemic)
        • 5.2.3.2. Intravenously (eg. insulin and GLP-1 receptor agonists)
      • 5.2.4. Global Antidiabetic Drug by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Antidiabetic Drug by: Drug Class (Value)
        • 5.2.5.1. Biguanides (Metformin)
        • 5.2.5.2. Sulfonylureas (Glimepiride)
        • 5.2.5.3. Meglitinides (Repaglinide)
        • 5.2.5.4. Thiazolidinediones (Pioglitazone)
        • 5.2.5.5. Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin)
        • 5.2.5.6. α-Glucosidase inhibitors (Acarbose)
      • 5.2.6. Global Antidiabetic Drug Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Antidiabetic Drug (Volume)
      • 5.3.1. Global Antidiabetic Drug by: Type (Volume)
        • 5.3.1.1. Type II Diabetes
      • 5.3.2. Global Antidiabetic Drug by: Drug Type (Volume)
        • 5.3.2.1. Generic
        • 5.3.2.2. Branded
      • 5.3.3. Global Antidiabetic Drug by: Route of Administration (Volume)
        • 5.3.3.1. Oral (eg. oral hypoglycemic)
        • 5.3.3.2. Intravenously (eg. insulin and GLP-1 receptor agonists)
      • 5.3.4. Global Antidiabetic Drug by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital Pharmacies
        • 5.3.4.2. Retail Pharmacies
        • 5.3.4.3. Online Pharmacies
      • 5.3.5. Global Antidiabetic Drug by: Drug Class (Volume)
        • 5.3.5.1. Biguanides (Metformin)
        • 5.3.5.2. Sulfonylureas (Glimepiride)
        • 5.3.5.3. Meglitinides (Repaglinide)
        • 5.3.5.4. Thiazolidinediones (Pioglitazone)
        • 5.3.5.5. Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin)
        • 5.3.5.6. α-Glucosidase inhibitors (Acarbose)
      • 5.3.6. Global Antidiabetic Drug Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Antidiabetic Drug (Price)
      • 5.4.1. Global Antidiabetic Drug by: Type (Price)
  • 6. Antidiabetic Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi-Aventis (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Oramed Pharmaceuticals (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Takeda Pharmaceuticals Private Limited (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Boehringer Ingelheim (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novo Nordisk (Denmark)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Halozyme Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol-Myers Squibb Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Tonghua Dongbao Pharmaceutical Co., Ltd. (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Astellas Pharma Inc.(Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Merck and Co.Inc.(United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. AstraZeneca plc (United Kingdom)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Antidiabetic Drug Sale, by Type, Drug Type, Route of Administration, Distribution Channel, Drug Class and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Antidiabetic Drug (Value)
      • 7.2.1. Global Antidiabetic Drug by: Type (Value)
        • 7.2.1.1. Type II Diabetes
      • 7.2.2. Global Antidiabetic Drug by: Drug Type (Value)
        • 7.2.2.1. Generic
        • 7.2.2.2. Branded
      • 7.2.3. Global Antidiabetic Drug by: Route of Administration (Value)
        • 7.2.3.1. Oral (eg. oral hypoglycemic)
        • 7.2.3.2. Intravenously (eg. insulin and GLP-1 receptor agonists)
      • 7.2.4. Global Antidiabetic Drug by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Antidiabetic Drug by: Drug Class (Value)
        • 7.2.5.1. Biguanides (Metformin)
        • 7.2.5.2. Sulfonylureas (Glimepiride)
        • 7.2.5.3. Meglitinides (Repaglinide)
        • 7.2.5.4. Thiazolidinediones (Pioglitazone)
        • 7.2.5.5. Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin)
        • 7.2.5.6. α-Glucosidase inhibitors (Acarbose)
      • 7.2.6. Global Antidiabetic Drug Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Antidiabetic Drug (Volume)
      • 7.3.1. Global Antidiabetic Drug by: Type (Volume)
        • 7.3.1.1. Type II Diabetes
      • 7.3.2. Global Antidiabetic Drug by: Drug Type (Volume)
        • 7.3.2.1. Generic
        • 7.3.2.2. Branded
      • 7.3.3. Global Antidiabetic Drug by: Route of Administration (Volume)
        • 7.3.3.1. Oral (eg. oral hypoglycemic)
        • 7.3.3.2. Intravenously (eg. insulin and GLP-1 receptor agonists)
      • 7.3.4. Global Antidiabetic Drug by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital Pharmacies
        • 7.3.4.2. Retail Pharmacies
        • 7.3.4.3. Online Pharmacies
      • 7.3.5. Global Antidiabetic Drug by: Drug Class (Volume)
        • 7.3.5.1. Biguanides (Metformin)
        • 7.3.5.2. Sulfonylureas (Glimepiride)
        • 7.3.5.3. Meglitinides (Repaglinide)
        • 7.3.5.4. Thiazolidinediones (Pioglitazone)
        • 7.3.5.5. Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin)
        • 7.3.5.6. α-Glucosidase inhibitors (Acarbose)
      • 7.3.6. Global Antidiabetic Drug Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Antidiabetic Drug (Price)
      • 7.4.1. Global Antidiabetic Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antidiabetic Drug: by Type(USD Million)
  • Table 2. Antidiabetic Drug Type II Diabetes , by Region USD Million (2015-2020)
  • Table 3. Antidiabetic Drug: by Drug Type(USD Million)
  • Table 4. Antidiabetic Drug Generic , by Region USD Million (2015-2020)
  • Table 5. Antidiabetic Drug Branded , by Region USD Million (2015-2020)
  • Table 6. Antidiabetic Drug: by Route of Administration(USD Million)
  • Table 7. Antidiabetic Drug Oral (eg. oral hypoglycemic) , by Region USD Million (2015-2020)
  • Table 8. Antidiabetic Drug Intravenously (eg. insulin and GLP-1 receptor agonists) , by Region USD Million (2015-2020)
  • Table 9. Antidiabetic Drug: by Distribution Channel(USD Million)
  • Table 10. Antidiabetic Drug Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 11. Antidiabetic Drug Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 12. Antidiabetic Drug Online Pharmacies , by Region USD Million (2015-2020)
  • Table 13. Antidiabetic Drug: by Drug Class(USD Million)
  • Table 14. Antidiabetic Drug Biguanides (Metformin) , by Region USD Million (2015-2020)
  • Table 15. Antidiabetic Drug Sulfonylureas (Glimepiride) , by Region USD Million (2015-2020)
  • Table 16. Antidiabetic Drug Meglitinides (Repaglinide) , by Region USD Million (2015-2020)
  • Table 17. Antidiabetic Drug Thiazolidinediones (Pioglitazone) , by Region USD Million (2015-2020)
  • Table 18. Antidiabetic Drug Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin) , by Region USD Million (2015-2020)
  • Table 19. Antidiabetic Drug α-Glucosidase inhibitors (Acarbose) , by Region USD Million (2015-2020)
  • Table 20. South America Antidiabetic Drug, by Country USD Million (2015-2020)
  • Table 21. South America Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 22. South America Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 23. South America Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 24. South America Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 25. South America Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 26. Brazil Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 27. Brazil Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 28. Brazil Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 29. Brazil Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 30. Brazil Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 31. Argentina Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 32. Argentina Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 33. Argentina Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 34. Argentina Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 35. Argentina Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 36. Rest of South America Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 37. Rest of South America Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 38. Rest of South America Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 39. Rest of South America Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 40. Rest of South America Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 41. Asia Pacific Antidiabetic Drug, by Country USD Million (2015-2020)
  • Table 42. Asia Pacific Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 43. Asia Pacific Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 44. Asia Pacific Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 45. Asia Pacific Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 46. Asia Pacific Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 47. China Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 48. China Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 49. China Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 50. China Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 51. China Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 52. Japan Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 53. Japan Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 54. Japan Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 55. Japan Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 56. Japan Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 57. India Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 58. India Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 59. India Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 60. India Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 61. India Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 62. South Korea Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 63. South Korea Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 64. South Korea Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 65. South Korea Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 66. South Korea Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 67. Taiwan Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 68. Taiwan Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 69. Taiwan Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 70. Taiwan Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 71. Taiwan Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 72. Australia Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 73. Australia Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 74. Australia Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 75. Australia Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 76. Australia Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 77. Rest of Asia-Pacific Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 78. Rest of Asia-Pacific Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 79. Rest of Asia-Pacific Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 82. Europe Antidiabetic Drug, by Country USD Million (2015-2020)
  • Table 83. Europe Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 84. Europe Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 85. Europe Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 86. Europe Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 87. Europe Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 88. Germany Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 89. Germany Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 90. Germany Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 91. Germany Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 92. Germany Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 93. France Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 94. France Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 95. France Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 96. France Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 97. France Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 98. Italy Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 99. Italy Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 100. Italy Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 101. Italy Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 102. Italy Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 103. United Kingdom Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 104. United Kingdom Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 105. United Kingdom Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 106. United Kingdom Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 107. United Kingdom Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 108. Netherlands Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 109. Netherlands Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 110. Netherlands Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 111. Netherlands Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 112. Netherlands Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 113. Rest of Europe Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 114. Rest of Europe Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 115. Rest of Europe Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 116. Rest of Europe Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 117. Rest of Europe Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 118. MEA Antidiabetic Drug, by Country USD Million (2015-2020)
  • Table 119. MEA Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 120. MEA Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 121. MEA Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 122. MEA Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 123. MEA Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 124. Middle East Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 125. Middle East Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 126. Middle East Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 127. Middle East Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 128. Middle East Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 129. Africa Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 130. Africa Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 131. Africa Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 132. Africa Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 133. Africa Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 134. North America Antidiabetic Drug, by Country USD Million (2015-2020)
  • Table 135. North America Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 136. North America Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 137. North America Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 138. North America Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 139. North America Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 140. United States Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 141. United States Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 142. United States Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 143. United States Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 144. United States Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 145. Canada Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 146. Canada Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 147. Canada Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 148. Canada Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 149. Canada Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 150. Mexico Antidiabetic Drug, by Type USD Million (2015-2020)
  • Table 151. Mexico Antidiabetic Drug, by Drug Type USD Million (2015-2020)
  • Table 152. Mexico Antidiabetic Drug, by Route of Administration USD Million (2015-2020)
  • Table 153. Mexico Antidiabetic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 154. Mexico Antidiabetic Drug, by Drug Class USD Million (2015-2020)
  • Table 155. Antidiabetic Drug Sales: by Type(K Units)
  • Table 156. Antidiabetic Drug Sales Type II Diabetes , by Region K Units (2015-2020)
  • Table 157. Antidiabetic Drug Sales: by Drug Type(K Units)
  • Table 158. Antidiabetic Drug Sales Generic , by Region K Units (2015-2020)
  • Table 159. Antidiabetic Drug Sales Branded , by Region K Units (2015-2020)
  • Table 160. Antidiabetic Drug Sales: by Route of Administration(K Units)
  • Table 161. Antidiabetic Drug Sales Oral (eg. oral hypoglycemic) , by Region K Units (2015-2020)
  • Table 162. Antidiabetic Drug Sales Intravenously (eg. insulin and GLP-1 receptor agonists) , by Region K Units (2015-2020)
  • Table 163. Antidiabetic Drug Sales: by Distribution Channel(K Units)
  • Table 164. Antidiabetic Drug Sales Hospital Pharmacies , by Region K Units (2015-2020)
  • Table 165. Antidiabetic Drug Sales Retail Pharmacies , by Region K Units (2015-2020)
  • Table 166. Antidiabetic Drug Sales Online Pharmacies , by Region K Units (2015-2020)
  • Table 167. Antidiabetic Drug Sales: by Drug Class(K Units)
  • Table 168. Antidiabetic Drug Sales Biguanides (Metformin) , by Region K Units (2015-2020)
  • Table 169. Antidiabetic Drug Sales Sulfonylureas (Glimepiride) , by Region K Units (2015-2020)
  • Table 170. Antidiabetic Drug Sales Meglitinides (Repaglinide) , by Region K Units (2015-2020)
  • Table 171. Antidiabetic Drug Sales Thiazolidinediones (Pioglitazone) , by Region K Units (2015-2020)
  • Table 172. Antidiabetic Drug Sales Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin) , by Region K Units (2015-2020)
  • Table 173. Antidiabetic Drug Sales α-Glucosidase inhibitors (Acarbose) , by Region K Units (2015-2020)
  • Table 174. South America Antidiabetic Drug Sales, by Country K Units (2015-2020)
  • Table 175. South America Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 176. South America Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 177. South America Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 178. South America Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 179. South America Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 180. Brazil Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 181. Brazil Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 182. Brazil Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 183. Brazil Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 184. Brazil Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 185. Argentina Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 186. Argentina Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 187. Argentina Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 188. Argentina Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 189. Argentina Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 190. Rest of South America Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 191. Rest of South America Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 192. Rest of South America Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 193. Rest of South America Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 194. Rest of South America Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 195. Asia Pacific Antidiabetic Drug Sales, by Country K Units (2015-2020)
  • Table 196. Asia Pacific Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 197. Asia Pacific Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 198. Asia Pacific Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 199. Asia Pacific Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 200. Asia Pacific Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 201. China Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 202. China Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 203. China Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 204. China Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 205. China Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 206. Japan Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 207. Japan Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 208. Japan Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 209. Japan Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 210. Japan Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 211. India Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 212. India Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 213. India Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 214. India Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 215. India Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 216. South Korea Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 217. South Korea Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 218. South Korea Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 219. South Korea Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 220. South Korea Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 221. Taiwan Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 222. Taiwan Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 223. Taiwan Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 224. Taiwan Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 225. Taiwan Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 226. Australia Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 227. Australia Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 228. Australia Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 229. Australia Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 230. Australia Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 231. Rest of Asia-Pacific Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 232. Rest of Asia-Pacific Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 233. Rest of Asia-Pacific Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 234. Rest of Asia-Pacific Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 235. Rest of Asia-Pacific Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 236. Europe Antidiabetic Drug Sales, by Country K Units (2015-2020)
  • Table 237. Europe Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 238. Europe Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 239. Europe Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 240. Europe Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 241. Europe Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 242. Germany Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 243. Germany Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 244. Germany Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 245. Germany Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 246. Germany Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 247. France Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 248. France Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 249. France Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 250. France Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 251. France Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 252. Italy Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 253. Italy Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 254. Italy Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 255. Italy Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 256. Italy Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 257. United Kingdom Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 258. United Kingdom Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 259. United Kingdom Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 260. United Kingdom Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 261. United Kingdom Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 262. Netherlands Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 263. Netherlands Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 264. Netherlands Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 265. Netherlands Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 266. Netherlands Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 267. Rest of Europe Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 268. Rest of Europe Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 269. Rest of Europe Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 270. Rest of Europe Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 271. Rest of Europe Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 272. MEA Antidiabetic Drug Sales, by Country K Units (2015-2020)
  • Table 273. MEA Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 274. MEA Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 275. MEA Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 276. MEA Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 277. MEA Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 278. Middle East Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 279. Middle East Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 280. Middle East Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 281. Middle East Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 282. Middle East Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 283. Africa Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 284. Africa Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 285. Africa Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 286. Africa Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 287. Africa Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 288. North America Antidiabetic Drug Sales, by Country K Units (2015-2020)
  • Table 289. North America Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 290. North America Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 291. North America Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 292. North America Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 293. North America Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 294. United States Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 295. United States Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 296. United States Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 297. United States Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 298. United States Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 299. Canada Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 300. Canada Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 301. Canada Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 302. Canada Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 303. Canada Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 304. Mexico Antidiabetic Drug Sales, by Type K Units (2015-2020)
  • Table 305. Mexico Antidiabetic Drug Sales, by Drug Type K Units (2015-2020)
  • Table 306. Mexico Antidiabetic Drug Sales, by Route of Administration K Units (2015-2020)
  • Table 307. Mexico Antidiabetic Drug Sales, by Distribution Channel K Units (2015-2020)
  • Table 308. Mexico Antidiabetic Drug Sales, by Drug Class K Units (2015-2020)
  • Table 309. Antidiabetic Drug: by Type(USD/Units)
  • Table 310. Company Basic Information, Sales Area and Its Competitors
  • Table 311. Company Basic Information, Sales Area and Its Competitors
  • Table 312. Company Basic Information, Sales Area and Its Competitors
  • Table 313. Company Basic Information, Sales Area and Its Competitors
  • Table 314. Company Basic Information, Sales Area and Its Competitors
  • Table 315. Company Basic Information, Sales Area and Its Competitors
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Antidiabetic Drug: by Type(USD Million)
  • Table 324. Antidiabetic Drug Type II Diabetes , by Region USD Million (2021-2026)
  • Table 325. Antidiabetic Drug: by Drug Type(USD Million)
  • Table 326. Antidiabetic Drug Generic , by Region USD Million (2021-2026)
  • Table 327. Antidiabetic Drug Branded , by Region USD Million (2021-2026)
  • Table 328. Antidiabetic Drug: by Route of Administration(USD Million)
  • Table 329. Antidiabetic Drug Oral (eg. oral hypoglycemic) , by Region USD Million (2021-2026)
  • Table 330. Antidiabetic Drug Intravenously (eg. insulin and GLP-1 receptor agonists) , by Region USD Million (2021-2026)
  • Table 331. Antidiabetic Drug: by Distribution Channel(USD Million)
  • Table 332. Antidiabetic Drug Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 333. Antidiabetic Drug Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 334. Antidiabetic Drug Online Pharmacies , by Region USD Million (2021-2026)
  • Table 335. Antidiabetic Drug: by Drug Class(USD Million)
  • Table 336. Antidiabetic Drug Biguanides (Metformin) , by Region USD Million (2021-2026)
  • Table 337. Antidiabetic Drug Sulfonylureas (Glimepiride) , by Region USD Million (2021-2026)
  • Table 338. Antidiabetic Drug Meglitinides (Repaglinide) , by Region USD Million (2021-2026)
  • Table 339. Antidiabetic Drug Thiazolidinediones (Pioglitazone) , by Region USD Million (2021-2026)
  • Table 340. Antidiabetic Drug Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin) , by Region USD Million (2021-2026)
  • Table 341. Antidiabetic Drug α-Glucosidase inhibitors (Acarbose) , by Region USD Million (2021-2026)
  • Table 342. South America Antidiabetic Drug, by Country USD Million (2021-2026)
  • Table 343. South America Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 344. South America Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 345. South America Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 346. South America Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 347. South America Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 348. Brazil Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 349. Brazil Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 350. Brazil Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 351. Brazil Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 352. Brazil Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 353. Argentina Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 354. Argentina Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 355. Argentina Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 356. Argentina Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 357. Argentina Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 358. Rest of South America Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 359. Rest of South America Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 360. Rest of South America Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 361. Rest of South America Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 362. Rest of South America Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 363. Asia Pacific Antidiabetic Drug, by Country USD Million (2021-2026)
  • Table 364. Asia Pacific Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 365. Asia Pacific Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 366. Asia Pacific Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 367. Asia Pacific Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 368. Asia Pacific Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 369. China Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 370. China Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 371. China Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 372. China Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 373. China Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 374. Japan Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 375. Japan Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 376. Japan Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 377. Japan Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 378. Japan Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 379. India Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 380. India Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 381. India Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 382. India Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 383. India Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 384. South Korea Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 385. South Korea Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 386. South Korea Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 387. South Korea Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 388. South Korea Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 389. Taiwan Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 390. Taiwan Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 391. Taiwan Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 392. Taiwan Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 393. Taiwan Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 394. Australia Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 395. Australia Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 396. Australia Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 397. Australia Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 398. Australia Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 399. Rest of Asia-Pacific Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 400. Rest of Asia-Pacific Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 401. Rest of Asia-Pacific Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 402. Rest of Asia-Pacific Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 403. Rest of Asia-Pacific Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 404. Europe Antidiabetic Drug, by Country USD Million (2021-2026)
  • Table 405. Europe Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 406. Europe Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 407. Europe Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 408. Europe Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 409. Europe Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 410. Germany Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 411. Germany Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 412. Germany Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 413. Germany Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 414. Germany Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 415. France Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 416. France Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 417. France Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 418. France Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 419. France Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 420. Italy Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 421. Italy Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 422. Italy Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 423. Italy Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 424. Italy Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 425. United Kingdom Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 426. United Kingdom Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 427. United Kingdom Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 428. United Kingdom Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 429. United Kingdom Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 430. Netherlands Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 431. Netherlands Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 432. Netherlands Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 433. Netherlands Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 434. Netherlands Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 435. Rest of Europe Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 436. Rest of Europe Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 437. Rest of Europe Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 438. Rest of Europe Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 439. Rest of Europe Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 440. MEA Antidiabetic Drug, by Country USD Million (2021-2026)
  • Table 441. MEA Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 442. MEA Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 443. MEA Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 444. MEA Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 445. MEA Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 446. Middle East Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 447. Middle East Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 448. Middle East Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 449. Middle East Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 450. Middle East Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 451. Africa Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 452. Africa Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 453. Africa Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 454. Africa Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 455. Africa Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 456. North America Antidiabetic Drug, by Country USD Million (2021-2026)
  • Table 457. North America Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 458. North America Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 459. North America Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 460. North America Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 461. North America Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 462. United States Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 463. United States Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 464. United States Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 465. United States Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 466. United States Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 467. Canada Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 468. Canada Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 469. Canada Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 470. Canada Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 471. Canada Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 472. Mexico Antidiabetic Drug, by Type USD Million (2021-2026)
  • Table 473. Mexico Antidiabetic Drug, by Drug Type USD Million (2021-2026)
  • Table 474. Mexico Antidiabetic Drug, by Route of Administration USD Million (2021-2026)
  • Table 475. Mexico Antidiabetic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 476. Mexico Antidiabetic Drug, by Drug Class USD Million (2021-2026)
  • Table 477. Antidiabetic Drug Sales: by Type(K Units)
  • Table 478. Antidiabetic Drug Sales Type II Diabetes , by Region K Units (2021-2026)
  • Table 479. Antidiabetic Drug Sales: by Drug Type(K Units)
  • Table 480. Antidiabetic Drug Sales Generic , by Region K Units (2021-2026)
  • Table 481. Antidiabetic Drug Sales Branded , by Region K Units (2021-2026)
  • Table 482. Antidiabetic Drug Sales: by Route of Administration(K Units)
  • Table 483. Antidiabetic Drug Sales Oral (eg. oral hypoglycemic) , by Region K Units (2021-2026)
  • Table 484. Antidiabetic Drug Sales Intravenously (eg. insulin and GLP-1 receptor agonists) , by Region K Units (2021-2026)
  • Table 485. Antidiabetic Drug Sales: by Distribution Channel(K Units)
  • Table 486. Antidiabetic Drug Sales Hospital Pharmacies , by Region K Units (2021-2026)
  • Table 487. Antidiabetic Drug Sales Retail Pharmacies , by Region K Units (2021-2026)
  • Table 488. Antidiabetic Drug Sales Online Pharmacies , by Region K Units (2021-2026)
  • Table 489. Antidiabetic Drug Sales: by Drug Class(K Units)
  • Table 490. Antidiabetic Drug Sales Biguanides (Metformin) , by Region K Units (2021-2026)
  • Table 491. Antidiabetic Drug Sales Sulfonylureas (Glimepiride) , by Region K Units (2021-2026)
  • Table 492. Antidiabetic Drug Sales Meglitinides (Repaglinide) , by Region K Units (2021-2026)
  • Table 493. Antidiabetic Drug Sales Thiazolidinediones (Pioglitazone) , by Region K Units (2021-2026)
  • Table 494. Antidiabetic Drug Sales Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin) , by Region K Units (2021-2026)
  • Table 495. Antidiabetic Drug Sales α-Glucosidase inhibitors (Acarbose) , by Region K Units (2021-2026)
  • Table 496. South America Antidiabetic Drug Sales, by Country K Units (2021-2026)
  • Table 497. South America Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 498. South America Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 499. South America Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 500. South America Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 501. South America Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 502. Brazil Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 503. Brazil Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 504. Brazil Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 505. Brazil Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 506. Brazil Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 507. Argentina Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 508. Argentina Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 509. Argentina Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 510. Argentina Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 511. Argentina Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 512. Rest of South America Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 513. Rest of South America Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 514. Rest of South America Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 515. Rest of South America Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 516. Rest of South America Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 517. Asia Pacific Antidiabetic Drug Sales, by Country K Units (2021-2026)
  • Table 518. Asia Pacific Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 519. Asia Pacific Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 520. Asia Pacific Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 521. Asia Pacific Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 522. Asia Pacific Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 523. China Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 524. China Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 525. China Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 526. China Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 527. China Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 528. Japan Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 529. Japan Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 530. Japan Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 531. Japan Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 532. Japan Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 533. India Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 534. India Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 535. India Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 536. India Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 537. India Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 538. South Korea Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 539. South Korea Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 540. South Korea Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 541. South Korea Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 542. South Korea Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 543. Taiwan Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 544. Taiwan Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 545. Taiwan Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 546. Taiwan Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 547. Taiwan Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 548. Australia Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 549. Australia Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 550. Australia Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 551. Australia Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 552. Australia Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 553. Rest of Asia-Pacific Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 554. Rest of Asia-Pacific Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 555. Rest of Asia-Pacific Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 556. Rest of Asia-Pacific Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 557. Rest of Asia-Pacific Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 558. Europe Antidiabetic Drug Sales, by Country K Units (2021-2026)
  • Table 559. Europe Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 560. Europe Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 561. Europe Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 562. Europe Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 563. Europe Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 564. Germany Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 565. Germany Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 566. Germany Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 567. Germany Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 568. Germany Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 569. France Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 570. France Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 571. France Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 572. France Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 573. France Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 574. Italy Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 575. Italy Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 576. Italy Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 577. Italy Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 578. Italy Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 579. United Kingdom Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 580. United Kingdom Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 581. United Kingdom Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 582. United Kingdom Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 583. United Kingdom Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 584. Netherlands Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 585. Netherlands Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 586. Netherlands Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 587. Netherlands Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 588. Netherlands Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 589. Rest of Europe Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 590. Rest of Europe Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 591. Rest of Europe Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 592. Rest of Europe Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 593. Rest of Europe Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 594. MEA Antidiabetic Drug Sales, by Country K Units (2021-2026)
  • Table 595. MEA Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 596. MEA Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 597. MEA Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 598. MEA Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 599. MEA Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 600. Middle East Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 601. Middle East Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 602. Middle East Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 603. Middle East Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 604. Middle East Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 605. Africa Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 606. Africa Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 607. Africa Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 608. Africa Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 609. Africa Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 610. North America Antidiabetic Drug Sales, by Country K Units (2021-2026)
  • Table 611. North America Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 612. North America Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 613. North America Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 614. North America Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 615. North America Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 616. United States Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 617. United States Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 618. United States Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 619. United States Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 620. United States Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 621. Canada Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 622. Canada Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 623. Canada Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 624. Canada Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 625. Canada Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 626. Mexico Antidiabetic Drug Sales, by Type K Units (2021-2026)
  • Table 627. Mexico Antidiabetic Drug Sales, by Drug Type K Units (2021-2026)
  • Table 628. Mexico Antidiabetic Drug Sales, by Route of Administration K Units (2021-2026)
  • Table 629. Mexico Antidiabetic Drug Sales, by Distribution Channel K Units (2021-2026)
  • Table 630. Mexico Antidiabetic Drug Sales, by Drug Class K Units (2021-2026)
  • Table 631. Antidiabetic Drug: by Type(USD/Units)
  • Table 632. Research Programs/Design for This Report
  • Table 633. Key Data Information from Secondary Sources
  • Table 634. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antidiabetic Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Antidiabetic Drug: by Drug Type USD Million (2015-2020)
  • Figure 6. Global Antidiabetic Drug: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Antidiabetic Drug: by Distribution Channel USD Million (2015-2020)
  • Figure 8. Global Antidiabetic Drug: by Drug Class USD Million (2015-2020)
  • Figure 9. South America Antidiabetic Drug Share (%), by Country
  • Figure 10. Asia Pacific Antidiabetic Drug Share (%), by Country
  • Figure 11. Europe Antidiabetic Drug Share (%), by Country
  • Figure 12. MEA Antidiabetic Drug Share (%), by Country
  • Figure 13. North America Antidiabetic Drug Share (%), by Country
  • Figure 14. Global Antidiabetic Drug: by Type K Units (2015-2020)
  • Figure 15. Global Antidiabetic Drug: by Drug Type K Units (2015-2020)
  • Figure 16. Global Antidiabetic Drug: by Route of Administration K Units (2015-2020)
  • Figure 17. Global Antidiabetic Drug: by Distribution Channel K Units (2015-2020)
  • Figure 18. Global Antidiabetic Drug: by Drug Class K Units (2015-2020)
  • Figure 19. South America Antidiabetic Drug Share (%), by Country
  • Figure 20. Asia Pacific Antidiabetic Drug Share (%), by Country
  • Figure 21. Europe Antidiabetic Drug Share (%), by Country
  • Figure 22. MEA Antidiabetic Drug Share (%), by Country
  • Figure 23. North America Antidiabetic Drug Share (%), by Country
  • Figure 24. Global Antidiabetic Drug: by Type USD/Units (2015-2020)
  • Figure 25. Global Antidiabetic Drug share by Players 2020 (%)
  • Figure 26. Global Antidiabetic Drug share by Players (Top 3) 2020(%)
  • Figure 27. Global Antidiabetic Drug share by Players (Top 5) 2020(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Sanofi-Aventis (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi-Aventis (France) Revenue: by Geography 2020
  • Figure 31. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 32. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 33. Oramed Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Oramed Pharmaceuticals (Israel) Revenue: by Geography 2020
  • Figure 35. Takeda Pharmaceuticals Private Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Takeda Pharmaceuticals Private Limited (Japan) Revenue: by Geography 2020
  • Figure 37. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 38. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 39. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 40. Novo Nordisk (Denmark) Revenue: by Geography 2020
  • Figure 41. Halozyme Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 42. Halozyme Therapeutics (United States) Revenue: by Geography 2020
  • Figure 43. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 44. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 45. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 47. Tonghua Dongbao Pharmaceutical Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 48. Tonghua Dongbao Pharmaceutical Co., Ltd. (China) Revenue: by Geography 2020
  • Figure 49. Astellas Pharma Inc.(Japan) Revenue, Net Income and Gross profit
  • Figure 50. Astellas Pharma Inc.(Japan) Revenue: by Geography 2020
  • Figure 51. Merck and Co.Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 52. Merck and Co.Inc.(United States) Revenue: by Geography 2020
  • Figure 53. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 54. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 55. Global Antidiabetic Drug: by Type USD Million (2021-2026)
  • Figure 56. Global Antidiabetic Drug: by Drug Type USD Million (2021-2026)
  • Figure 57. Global Antidiabetic Drug: by Route of Administration USD Million (2021-2026)
  • Figure 58. Global Antidiabetic Drug: by Distribution Channel USD Million (2021-2026)
  • Figure 59. Global Antidiabetic Drug: by Drug Class USD Million (2021-2026)
  • Figure 60. South America Antidiabetic Drug Share (%), by Country
  • Figure 61. Asia Pacific Antidiabetic Drug Share (%), by Country
  • Figure 62. Europe Antidiabetic Drug Share (%), by Country
  • Figure 63. MEA Antidiabetic Drug Share (%), by Country
  • Figure 64. North America Antidiabetic Drug Share (%), by Country
  • Figure 65. Global Antidiabetic Drug: by Type K Units (2021-2026)
  • Figure 66. Global Antidiabetic Drug: by Drug Type K Units (2021-2026)
  • Figure 67. Global Antidiabetic Drug: by Route of Administration K Units (2021-2026)
  • Figure 68. Global Antidiabetic Drug: by Distribution Channel K Units (2021-2026)
  • Figure 69. Global Antidiabetic Drug: by Drug Class K Units (2021-2026)
  • Figure 70. South America Antidiabetic Drug Share (%), by Country
  • Figure 71. Asia Pacific Antidiabetic Drug Share (%), by Country
  • Figure 72. Europe Antidiabetic Drug Share (%), by Country
  • Figure 73. MEA Antidiabetic Drug Share (%), by Country
  • Figure 74. North America Antidiabetic Drug Share (%), by Country
  • Figure 75. Global Antidiabetic Drug: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Sanofi-Aventis (France)
  • Eli Lilly and Company (United States)
  • Oramed Pharmaceuticals (Israel)
  • Takeda Pharmaceuticals Private Limited (Japan)
  • Boehringer Ingelheim (Germany)
  • Novo Nordisk (Denmark)
  • Halozyme Therapeutics (United States)
  • Bristol-Myers Squibb Company (United States)
  • Pfizer Inc. (United States)
  • Tonghua Dongbao Pharmaceutical Co., Ltd. (China)
  • Astellas Pharma Inc.(Japan)
  • Merck and Co.Inc.(United States)
  • AstraZeneca plc (United Kingdom)
Additional players considered in the study are as follows:
Janssen Pharmaceuticals, Inc.(Belgium) , Biocon (India) , Wockhardt Limited (India)
Select User Access Type

Key Highlights of Report


Jun 2021 230 Pages 82 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antidiabetic Drug Market Quantitative research analysis
Global Antidiabetic Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Antidiabetic Drug market is expected to see a growth of 7.35% during projected year 2020 to 2026.
The prominent players of Global Antidiabetic Drug market are Sanofi-Aventis (France), Eli Lilly and Company (United States), Oramed Pharmaceuticals (Israel), Takeda Pharmaceuticals Private Limited (Japan), Boehringer Ingelheim (Germany), Novo Nordisk (Denmark), Halozyme Therapeutics (United States), Bristol-Myers Squibb Company (United States), Pfizer Inc. (United States), Tonghua Dongbao Pharmaceutical Co., Ltd. (China), Astellas Pharma Inc.(Japan), Merck and Co.Inc.(United States) and AstraZeneca plc (United Kingdom), to name a few.
In this highly competitive & fast evolving Antidiabetic Drug industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Antidiabetic Drug Market Report?

Have a Query? Click Here

Other Related Reports

Acyclovir Drug Comprehensive Study by Application (Hospital, Drug Store), Form (Oral, Topical, Injection), Distribution Channel (Drugstores, Online Retails, Independent Retailers and Discounters) Pla...
$ 3500
Liver Health Supplements Comprehensive Study by Type (Vitamins, Minerals, Herbal Supplements, Others), Application (Hospital, Pharmacies, Retail Pharmacies, Online Pharmacies), Form (Tablet, Liquid, ...
$ 3500
Weight Gain Supplements Comprehensive Study by Type (Whey protein, Creatine, Weight gainers, Others (Exercise-Enhancing Supplements)), Application (Supermarkets/Hypermarkets, Drug Stores, Convenience...
$ 3750
Microneedling Cartridges Comprehensive Study by Number of Needle (1-6 microneedle, 12-36 microneedle), Distribution Channel (Online, Offline), Material (Steel, Titanium, Others), End User (Hospitals,...
$ 3350
Honeysuckle Extract Comprehensive Study by Type (Powder, Liquid, Capsules), Application (Pharmaceutical, Food and Beverages, Personal Care, Supplements, Pharmaceuticals, Cosmetics, Others), (), Dist...
$ 3650
Antiseptic Bathing Comprehensive Study by Type (CHG Bath Wipes, CHG Solution, Antiseptic Wipes, Antiseptic Bathing Solution, Others), Distribution Channel (Online, Offline), End-Use (ICU, Surgical Wa...
$ 3800